Droloxifene—A New Anti-Estrogen; A phase II study in advanced breast cancer

References

• Early Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28 896 women. N Eng J Med 1988; 319: 1681–92
   PubMed Web of Science ®Google Scholar
• Pritchard K I, Sutherland D JA. The use of endocrine therapy. In: diagnosis and treatment of breast cancer. Hematol Oncol Clin North Am 1989; 3: 765–805
   PubMed Web of Science ®Google Scholar
• Buckley M M-T, Goa K L. Nolvadex (tamoxifen): a review. Drugs 1989; 37: 451–90
   PubMed Web of Science ®Google Scholar
• Kvinnsland S. How to improve endocrine therapy in breast cancer. Acta Oncol 1990; 29: 387–9
   PubMed Web of Science ®Google Scholar
• Kangas L, Nieminen A-L, Blanco G, et al. A new triphenylethylene compound, Gc-1157a. II. Antitumor effects. Cancer Chemother Pharmacol 1986; 17: 109–13
   PubMed Web of Science ®Google Scholar
• Roos W, Oeze L, Løser R, Eppenberger U. Antiestrogenic action of 3-hydroxytamoxifen in the human breast cancer cell line MCF-7. JNCI 1983; 71: 55–9
   PubMed Web of Science ®Google Scholar
• Huber H-J, Stanislaus F, Jank P, Janzen N, Kern D. Pharmacokinetics and metabolism of 3-OH-tamoxifen-citrate in laboratory animals. Proc. of the annual meeting ‘Deutsche Pharmazeutische Gesellschaft’. Dusseldorf. 1984. FRG
   Google Scholar
• Grill H J, Pollow K. Pharmacokinetics of Droloxifene and its metabolites in breast cancer patients (abstract 11. 04). Proc. 15th International Cancer Congress. 1990, 116, Hamburg. J Cancer Res Clin Oncol;Suppl
   Google Scholar
• Kvinnsland S. Droloxifene, a new antiestrogen. Hormonal influences in postmenopausal breast cancer patients. Am J Clin Oncol 1991, accepted for publication
   PubMed Web of Science ®Google Scholar
• Eppendberger U, Hasmann M, Küng W, Wosikowski K, Seibel K, Löser R. Pharmacological properties of Droloxifene (abstract 10.11. 02). Proc. 15th International Cancer Congress, Hamburg. 1990. 116, J Cancer Res Clin Oncol(Suppl)
   Google Scholar
• Hayward J L, Carbone P P, Heuson J-C, Kumaoka S, Segaloff A, Rubens R D. Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977; 13: 89–94
   Web of Science ®Google Scholar
• Rossner S, Wallgren A. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 1984; 52: 39–46
   Web of Science ®Google Scholar
• Bertelli G, Pronzoto P, Amoroso D. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 1988; 12: 307–10
   PubMed Web of Science ®Google Scholar
• Turken S, Siris E, Seldin E, et al. Effects of tamoxifen on spinal bone density in women with breast cancer. JNCI 1989; 81: 1086–8
   PubMed Web of Science ®Google Scholar
• Fornander T, Rutquist L E, Sjöberg H E, Blomquist L, Mattson A, Glas U. Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncol 1990; 8: 1019–23
   PubMed Web of Science ®Google Scholar
• Fornander T, Rutquist L E, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1: 117–20
   PubMed Web of Science ®Google Scholar
• Kvinnsland S, Gundersen S. Prospects for alternating endocrine therapy. Endocrine management of cancer, B Stoll. Karger, Basel 1988; 119–25
   Google Scholar
• Dietel M, Loser R, Rohlke P, et al. Effect of continuous vs intermittent application of 3-OH-tamoxifen or tamoxifen on the proliferation of the human breast cancer cell line KCF-7 MI. J Cancer Res Clin Oncol 1989; 115: 36–40
   PubMed Web of Science ®Google Scholar
• Rattel B, Loser R, Dahme E G, Liehn H D, Seibel K. Comparative toxicology of Droloxifene (3-OH-tamoxifen) and tamoxifen; hepatocellular carcinomas induced by tamoxifen. Biennal International Breast Cancer Conference, Miami, FL, 1987, 18
   Google Scholar
• Abe O, Japanese Droloxifene study group. Japanese early phase II studies—a preliminary dose finding study (abstract 10.11.07). Proc. 15th International Cancer Congress. 1990. 116: 930, J Cancer Res Clin Oncol(suppl., part 11)
   Google Scholar
• Sole L A. European early phase 11 dose-finding study of Droloxifene in advanced breast cancer. IBID, 930, abstract 10.11. 06). for Droloxifene 001 International Study Group
   Google Scholar
• Deschenes L. Double-blind phase II dose ranging study protocol with Droloxifene. 930, abstract 10.11.08). for Droloxifene 002 International Study Group
   Google Scholar